CHARLESSON LLC
- OKLAHOMA CITY, OK 73105-1806
- Partnership or Limited Liability Partnership
- SAM active
- No verified credentials yet
- CMMCNot on file
- SPRSNone
- FCLVisible to paid members
- Small Business
- Women-Owned Small Business
Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works
- 36-mo obligations
- $39.5K
- Awards on record
- 1
- Contract vehicles
- 0
- Verified credentials
- 0
Compliance posture: unverified (SAM.gov baseline only)
CHARLESSON LLC has not claimed this profile. What you see comes from public SAM.gov and USAspending records; no one from the company has confirmed CMMC, SPRS or clearance details yet. Learn more about CMMC 2.0
About CHARLESSON LLC
- Headquarters
- OKLAHOMA CITY, OK 73105-1806
Identifiers
UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.
- UEIEBG6FJ52JJX3
- CAGE486U5
Capabilities & differentiators
No capability narrative yet
Compliance posture
No compliance posture published yet
Facility clearance
Facility clearance: visible to paid members
Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans
Past performance
- 36-month obligations
- $39.5K
- Awards on record
- 1
- Top funding agencies
- Department of Veterans Affairs
Awards
36C25220C0212
Completed: Period of performance ended May 30, 2025RESEARCH MODELS OF MIXED DRY EYE DISEASE IN MICE - EYECRO LLC
Department of Veterans Affairs
- Obligated
- $39.5K
- Period of performance
- Sep 30, 2020 – May 30, 2025
| Award | Agency | NAICS · PSC | Obligated | Period of performance | Recompete |
|---|---|---|---|---|---|
36C25220C0212 RESEARCH MODELS OF MIXED DRY EYE DISEASE IN MICE - EYECRO LLC | Department of Veterans Affairs | 541714 · AN11HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH | $39.5K | Sep 30, 2020 – May 30, 2025 | Completed: Period of performance ended May 30, 2025 |
Contract vehicles
No contract vehicles on file
Proven teaming graph
No sub-award reports yet
Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.
SBIR/STTR portfolio
SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects
Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.
- Awards on record
- 23 awards
- Total awarded
- $10,337,136
- By phase
- SBIR Phase I: 19
- SBIR Phase II: 4
- By agency
- Department of Health and Human Services: 23
- Active projects
- 0 projects
- Projects whose contract end date is today or later.
- Phase II ending within 12 months
- 0 projects
- Phase II projects ending within 12 months. Agencies may award Phase III work without a new competition only when it derives from, extends or completes these projects.
- By year
- 2016: 1
- 2015: 2
- 2014: 1
- 2013: 1
- 2012: 1
- 2011: 3
- 2009: 2
- 2008: 3
- 2007: 3
- 2006: 2
- 2005: 3
- 2004: 1
Awards (most recent first)
Fenofibrate Eye Drop for the Treatment of Diabetic Retinopathy
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2016 · $185,550
Sep 1, 2016 – Aug 31, 2018
Solicitation PA14-071 (2014) · Topic N
Developing A Novel Therapy for Diabetic Retinopathy
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2015 · $1,495,545
Sep 30, 2015 – Aug 31, 2018
Solicitation PA14-071 (2014) · Topic W
A Novel Therapeutic Antibody for Age-related Macular Degeneration
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2015 · $225,000
Aug 1, 2015 – Jul 31, 2016
Solicitation PA14-071 (2015) · Topic W
A Wnt Modulator for Treatment of Age-related Macular Degeneration
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2014 · $225,000
Solicitation PA13-088 (2014) · Topic NEI · Research partner: Stub
Developing A Novel Therapy for Diabetic Retinopathy
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2013 · $246,418
Solicitation PA12-088 (2013) · Topic NEI · Research partner: Stub
A Small Molecule Targeting Wnt Pathway for Treatment of Diabetic Retinopathy
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2012 · $231,087
Solicitation PA11-096 (2012) · Topic NEI · Research partner: Stub
Multitargeted Therapy for Age-related Macular Degeneration
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2011 · $265,992
Solicitation PA10-050 (2011) · Topic NEI · Research partner: Stub
Novel emulsion-based formulation of the anti-glaucoma MSH-1001 for improved topic
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2011 · $287,947
Solicitation PA10-050 (2011) · Topic NEI · Research partner: Stub
Safety and Toxicology Studies of CLT-005 as a Therapeutic for Diabetic Macular Ed
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2011 · $2,685,795
Solicitation PA10-050 (2011) · Topic NEI · Research partner: Stub
Novel Antioxidants for Treatment of Diabetic Retinopathy
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2009 · $248,094
Solicitation PHS2009-2 (2009)
Development of a novel anti-inflammatory treatment for clinical management of end
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2009 · $227,286
Solicitation PHS2009-2 (2009)
Development of a genetic CNV model for Age-Related Macular Degeneration
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2008 · $210,357
Solicitation PHS2007-2 (2008)
A novel Stat3 inhibitor for treating retinal inflammation and neovascularization
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2008 · $241,279
Solicitation PHS2007-2 (2008)
Sustained delivery of linomide-5 for diabetic retinopathy and macular degeneratio
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2008 · $1,388,680
Solicitation PHS2007-2 (2008)
Novel Combretastatin A4 analogs for Treatment of Retinal Neovascularization
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2007 · $237,429
Solicitation year 2007
Nanotechnology for Treatment of Diabetic Retinopathy
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2007 · $570,438
Solicitation year 2007
A Novel Thalidomide Analog for the Treatment of Diabetic Macular Edema
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2007 · $449,845
Solicitation year 2007
Cocktail of Angiogenic Inhibitors for the Treatment of Diabetic Macular Edema
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2006 · $133,750
Solicitation PHS2006-2 (2006)
Novel Linomide Analog for Treatment of Diabetic Retinopathy
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2006 · $248,294
Solicitation PHS2006-2 (2006)
Treatment of Retinal Vascular Leakage Using Angiostatin
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2005 · $149,800
Solicitation PHS2005-2 (2005)
New Thalidomide Analogs for Retinal Neovacularization
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2005 · $149,800
Solicitation PHS2005-2 (2005)
Peptide Eyedrops for Treatment of Diabetic Retinopathy
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2005 · $133,750
Solicitation PHS2005-2 (2005)
Release of Angiogenic Inhibitors for Macular Edema
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2004 · $100,000
Solicitation PHS2004-2 (2004)
Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026
FedRAMP offerings
No FedRAMP Marketplace listing
Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded
Exclusions & screening
SAM.gov exclusions
Not yet checked against SAM.gov exclusions.
Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.
Source: SAM.gov Exclusions (opens in a new tab) · sync date not recorded
Consolidated Screening List
No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).
The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.
Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 13, 2026
GSA CALC+ rate benchmark
No GSA CALC+ rates on record
Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded
NAICS, PSC & socio-economic status
NAICS codes
- 541714Research and Development in Biotechnology (except Nanobiotechnology)PrimarySmall business under this code’s size standard
SAM.gov reports this entity as small under 1 of 1 NAICS code. Size is determined per code (SBA size standards).
Socio-economic status
Self-represented in SAM.gov. WOSB and EDWOSB set-asides need SBA certification (13 CFR 127.300); SDVOSB and VOSB need SBA VetCert (13 CFR part 128). Confirm current certification before relying on it.
Learn more about small business set-asidesProduct & service codes (PSC)
No PSC codes reported.
Teaming preferences
This company has not published teaming preferences.
Business development contact
No BD contact published
Corporate hierarchy
No parent entity reported in SAM.gov.
SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.
Data sources & provenance
SAM.gov
Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.
USAspending.gov
Prime award history and obligations (FPDS), synced nightly.
The contractor
Nothing yet: this profile has not been claimed by the company.
TeamingIndex verification
Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.
Corrections
Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)
Machine-readable: capability.md schema.org JSON-LD embedded in this page.
Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.
Teaming
Ready to team with CHARLESSON LLC?
Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.